Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 6

  • 837 clinical trials
  • 354 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Systemic scleroderma39Pulmonary arterial hypertension38Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension27Pulmonary hypertension23Acute coronary syndrome21Giant cell arteritis18Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Paroxysmal nocturnal haemoglobinuria15Cerebrovascular accident14Pulmonary embolism14Anti-neutrophil cytoplasmic antibody positive vasculitis13Diabetic foot13Embolism13Myocardial infarction13+354

Clinical trials in Vascular disorders

837 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

837 clinical trials

A study evaluating the efficacy and safety of secukinumab compared to a drug combination in patients with severe Takayasu arteritis.

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Still's disease+1

Recruiting
InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Herpes ophthalmic+1

Recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AGANIRSEN
  • Sponsor:University Of Cologne

Pulmonary arterial hypertension

Recruiting
InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ROC-101 HYDROCHLORIDE
  • Sponsor:Allrock Bio Inc.

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Giant cell arteritis

Recruiting
InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Arteriosclerosis

Recruiting
Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Acute myocardial infarction+1

Recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Humanitas Mirasole S.p.A.

Corneal neovascularisation

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:AGANIRSEN
  • Sponsor:University Of Cologne

Mitral valve disease+2

Recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SP16
  • Sponsor:Universitaetsklinikum Erlangen AöR

Acute coronary syndrome

Recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Ferric Carboxymaltose
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

Haemorrhagic stroke

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN PLASMA
  • Sponsor:Johannes Kepler University Linz

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.